01—Abstract
Summary
Summary of the 10-Q filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) reported third-quarter 2024 net income attributable to Royalty Pharma plc of $543,987 thousanda ($1.22 basic EPS), compared with $72,114 thousand ($0.16) in the third quarter of 2023.
Consolidated net income before tax was $806,358 thousandb versus $122,077 thousand a year earlier. The quarter's results were lifted by a $227.6 million provision for changes in expected cash flows (income, versus $277.1 million of expense in Q3 2023) and by $127.4 million of other income, primarily gains on available-for-sale debt securities and equity securities. Total income and other revenues rose 5.3% to $564.7 million in the quarter, while income from financial royalty assets was $533.2 million for the quarter and $1.59 billion for the first nine months, down from $1.67 billion a year earlier, largely because of a non-recurring $475.0 million Zavzpret milestone in the first quarter of 2023.
Portfolio Receipts were $734.6 millionc in the third quarter, up 15.3%, and $2.06 billion for the first nine months, down 10.9% from $2.31 billion, reflecting the prior-year milestone. Cash from operating activities for the first nine months was $2.03 billion. The company invested $2.2 billion in royalties, milestones and other contractual receipts in the first nine months, and in November 2024 it acquired a Niktimvo royalty for a $350 million upfront payment.
Total debt principal was $7.8 billiond at September 30, 2024, after the June 2024 issuance of $1.5 billion of senior unsecured notes, and cash and cash equivalents were $950.1 million. Shareholders received $282.8 million in dividends ($0.21 per Class A share in each of three quarterly payments) during the first nine months, and the company repurchased 6.6 million Class A shares for about $179.7 million, with $515.6 million remaining under the $1.0 billion authorization. Vertex accounted for 36% of total income and other revenues in the third quarter of 2024 (41% in the prior-year quarter).
02—Key points
Key Highlights
- Net income attributable to Royalty Pharma plc was $543,987 thousand in Q3 2024 versus $72,114 thousand in Q3 2023; basic EPS was $1.22 versus $0.16.
- Q3 2024 included a $227.6 million provision benefit for changes in expected cash flows, compared with $277.1 million of provision expense in Q3 2023.
- Portfolio Receipts were $734.6 million in Q3 2024, up 15.3%, and $2.06 billion for the first nine months, down 10.9% from the prior-year period that included a $475.0 million Zavzpret milestone.
- Total debt principal rose to $7.8 billion at September 30, 2024, following the $1.5 billion of senior unsecured notes issued in June 2024; cash and cash equivalents were $950.1 million.
- The company invested $2.2 billion in royalties, milestones and other contractual receipts in the first nine months of 2024, including Voranigo, frexalimab, Yorvipath and Evrysdi royalty transactions.
- A subsequent event: in November 2024 the company acquired a royalty on Niktimvo from Syndax Pharmaceuticals for a $350 million upfront payment.
- Shareholders received $282.8 million in dividends and the company repurchased 6.6 million Class A shares for about $179.7 million in the first nine months, with $515.6 million remaining under the share repurchase program.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed November 6, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $564.69M$536.31M | +5.3% |
| R&D Expenses | $500K$50.50M | −99.0% |
| Operating Expenses | -$170.38M$384.87M | −144.3% |
| Operating Income | $735.07M$151.44M | +385.4% |
| Net Income | $543.99M$72.11M | +654.3% |
| EPS (Basic) | $1.22$0.16 | +662.5% |
| EPS (Diluted) | $1.21$0.16 | +656.3% |
| Shares Outstanding (Basic) | 447.63M448.44M | −0.2% |
| Shares Outstanding (Diluted) | 592.73M601.14M | −1.4% |
05—Questions
Frequently Asked Questions
Why did net income rise so sharply in the third quarter of 2024?
Consolidated net income before tax was $806.4 million in Q3 2024 versus $122.1 million in Q3 2023. The filing attributes much of the change to a $227.6 million provision benefit for changes in expected cash flows from financial royalty assets, compared with $277.1 million of expense a year earlier, and to other income of $127.4 million, including $57.7 million of gains on available-for-sale debt securities and $50.8 million of gains on equity securities. The filing notes that this income statement activity is non-cash and can be volatile.
How did cash generation trend, and how does Portfolio Receipts compare with GAAP income?
Net cash provided by operating activities was $2.03 billion for the first nine months of 2024 versus $2.22 billion a year earlier. Portfolio Receipts, the company's key performance metric, were $734.6 million in Q3 2024 and $2.06 billion for the first nine months, the latter down 10.9% from $2.31 billion because the prior-year period included a $475.0 million Zavzpret milestone. The filing states that there is no direct correlation between income from financial royalty assets and royalty receipts.
How is the balance sheet positioned after the debt issuance?
Total debt principal was $7.8 billion at September 30, 2024, versus $6.3 billion at December 31, 2023, following $1.5 billion of senior unsecured notes issued in June 2024. The current portion of long-term debt was $996.9 million, with $1.0 billion of notes maturing in September 2025. Cash and cash equivalents were $950.1 million, and the company had $1.8 billion of revolving commitments available under its Revolving Credit Facility, with no borrowings outstanding.
How concentrated is the portfolio?
Vertex, as marketer of the cystic fibrosis franchise, accounted for 36% of total income and other revenues in Q3 2024 and 37% for the first nine months. Roche accounted for 10% in Q3 2024 and for the first nine months. The filing also states that the top five product franchises accounted for 64% of Royalty Receipts in the first nine months of 2024.
What capital returns did shareholders receive?
The company declared and paid three quarterly cash dividends of $0.21 per Class A ordinary share in the first nine months of 2024, totaling $282.8 million. It repurchased 3,477 thousand Class A shares in Q3 2024 at an average price of $27.40, and 6.6 million shares for about $179.7 million in the first nine months. Approximately $515.6 million remained available under the $1.0 billion repurchase authorization as of September 30, 2024.
06—Continue